Evans syndrome (ES) is a haematological disorder characterised by the simultaneous or sequential development of autoimmune thrombocytopenia (AITP) and autoimmune haemolytic anaemia (AIHA). Haematopoietic SCT (HSCT) is an effective treatment for autoimmune cytopenias such as AITP, AIHA and ES. In patients who are successfully treated, self-reacting lymphocyte clones could be eliminated or inhibited with myeloablative conditioning and/or through the graft versus autoimmunity (GVA) effect, such that a cure or long-term remission is reasonably expected at the cost of the toxicity associated with HSCT. 1 A 10-year-old boy was diagnosed with AIHA in November 2004. Although he responded to corticosteroid (CS), repeated recurrence was observed when the CS dose was tapered off. Fluctuating thrombocytopenia was identified in September 2006, and thus a diagnosis of ES was made. No underlying disease including autoimmune lymphoproliferative syndrome (ALPS) was identified. 2 While fluctuating, the number of thrombocytes would sometimes fall to 1 Â 10 9 /L or less. Intracranial haemorrhage, severe epistaxis and buccal bleeding occurred during the clinical course. Although multiple therapeutic options that are reportedly effective for the treatment of ES, including high-dose intravenous immunoglobulin infusion (IVIG), CsA, rituximab, cepharanthine, vincristine, mycophenolate mofetil, 6-mercaptopurine, dapsone, danazol, and high-dose CY together with splenectomy and accessory splenectomy, had been used since the onset of ES, the results were unsatisfactory (Figure 1) .
Among the treatments, the patient had been given prednisolone and CsA for 6 and 2 years, respectively, at variable doses. He had a Cushingoid appearance, short stature, acne and verrucae on the skin, a compression fracture of a lumbar vertebra, chronic intermittent headache, stiffness of the muscles, insomnia, lymphocytopenia and osteoporosis, which were thought to be adverse effects due to one of these two agents.
As the patient has an identical twin brother, a syngeneic HSCT was planned because no other treatment modality was considered promising. Withdrawal from CS and CsA, which had been given for an extended period, was also thought to be desirable. The donor-to-be brother was completely healthy with no evidence of ALPS. The suggestion of syngeneic HSCT was made to the patient, the parents and the brother, and written consent from the family was obtained.
The conditioning regimen consisted of CY at a dose of 50 mg/kg/day i.v. infusion from day À 4 to À 1 before the transplant. The donor was given G-CSF for mobilisation. A total of 7.7 Â 10 8 /kg of unmanipulated PBMC (3.8 Â 10 6 /kg of CD34-positive cells) was harvested and infused into the patient in October 2010.
Neutrophil recovery (0.5 Â 10 9 /L) was identified on day 10. The patient's platelet level reached a normal level on day 180. His platelet count and Hb level at 8 months post transplantation were 17.3 Â 10 9 /L and 14.7 g/dL, respectively. The patient remains in remission without therapy 17 months after the syngeneic PBSCT, the longest remission period ever experienced by this patient (Figure 1 ). Of note, although the levels of haptoglobin, indirect bilirubin, aspartate transaminase, lactate dehydrogenase and reticulocytes are normal, the direct Coombs test remains positive up to day 582, suggesting that minimal autoantibody is being produced by long-lived plasma cells with limited extravascular haemolysis due to splenectomy and accessory splenectomy. In this case, however, the patient is still deemed to be in CR by the definition of Passweg. 1 We surveyed the literature and identified 18 reports detailing a total of 23 patients with ES treated with 26 HSCTs. The definitions of CR, relapse (REL) and treatment-related mortality (TRM) used herein are defined using the definitions of Passweg.
1 The median age of the patients who underwent HSCT is 21 years. The median time course from the onset of the disease to HSCT is 5.42 years, and a median of seven treatment modalities were used before HSCT. Of the 26 HSCTs, 15 were autologous and 11 were allogeneic. CD34-positive cell selection was employed in all of the autologous HSCTs except for 2, for which the details were not described. The results were compared between autologous and allogeneic HSCTs (Table 1) . More patients who underwent allogeneic HSCT likely achieved CR than patients who underwent autologous HSCT at the cost of therapeutic toxicity: CR was attained in 4 out of 15 autologous transplantations and in 8 out of 11 allogeneic transplantations. REL occurred in 5 out of 15 patients who underwent autologous transplantation. A list of information on patients and HSCTs collected here and organised in a table can be provided upon request.
We reasoned that HSCT is indicated for those cases with ES (i) when continued immunosuppressive intervention reduced the quality of life of the patients and (ii) when the disease activity is not satisfactorily controlled with the conventional therapy described herein or elsewhere. 3 The indications for HSCT in the present case are in line with the current EBMT autoimmune diseases working party guidelines, which describe the indications for HSCT as a treatment for immune cytopenia, paediatric cases and syngeneic transplantation. 4 Recently, TPO receptor antagonists have become a promising treatment option for chronic AITP. The indications for HSCT for the treatment of ES could therefore be revised if TPO receptor antagonists are demonstrated to be effective for the control of thrombocytopenia in patients with ES. However, future evaluations are required to determine the long-term therapeutic significance of these drugs.
A syngeneic immune system has been reported to cause a graft versus host reaction, possibly due to post-somatic modification. 5 Studies comparing the T-cell repertoire before and after the transplantation could have scientific significance. A prospective study and material banking should provide some information on the possible effects of GVA in syngeneic transplantation.
Zayden et al. 6 reported effective syngeneic PBSCT for a case of chronic ITP. They employed reduced myeloablative conditioning with CY and TBI. The patient had been in CR for 12 months after the syngeneic HSCT without any transplantation-related toxicity. Their experience and ours suggests that when available, a syngeneic transplant could be the preferred treatment if the expected outcomes of conventional therapies are sufficiently 
